Karen H. Lu, MD, on Next Steps in Evaluating Genetic Testing in Underrepresented Minorities
The MD Anderson Cancer Center expert discussed further research in delivering online accessible genetic testing.
Related Articles
Alectinib Significantly Improves DFS Vs Chemo in Resected ALK+ NSCLC
Investigators of the phase 3 ALINA trial report no unexpected safety findings with alectinib in ALK-positive non–small cell lung cancer.
FDA Approves Second-Line Tislelizumab Monotherapy in Esophageal Cancer
Results from the phase 3 RATIONALE 302 trial led to the approval of tislelizumab for patients with unresectable or metastatic esophageal squamous cell carcinoma.
Tislelizumab Earns European Approval in Non–Small Cell Lung Cancer
A series of phase 3 findings support the European approval of tislelizumab as a first-line and second-line treatment for non–small cell lung cancer.
ME-344/Bevacizumab Combo Shows Early Efficacy in mCRC
ME-344 and bevacizumab can now have an additional 20 patients enrolled on the phase 1b trial for relapsed metastatic colorectal cancer.
FDA Approves Tovorafenib for Relapsed/Refractory Low-Grade Glioma
The FDA approval of the single-agent, oral pan-RAF inhibitor tovorafenib is based on efficacy results from the phase 2 FIREFLY-1 trial.
7-Gene Predictive Biosignature Helps Predict Ipsilateral Breast Cancer Recurrence
DCISionRT is a risk-assessment test for patients designed to predict RT benefit and develop their recurrence risk after surgery alone or with radiation.
FDA Approves Lutetium Lu 177 Dotatate in Pediatric SSTR+ GEP-NETs
Data from 2 NETTER trials support lutetium Lu 177 dotatate’s approval in somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
FDA Approves Nogapendekin Alfa-inbakicept/BCG in BCG-unresponsive NMIBC
Nogapendekin alfa-inbakicept is now approved for the treatment of patients with BCG-unresponsive non-muscle invasive bladder carcinoma.
Neoadjuvant/Adjuvant Pembrolizumab Regimens Lower RCB in ER+ Breast Cancer
The latest KEYNOTE-756 data highlight the surgical outcomes of patients with high-risk early-stage estrogen receptor–positive breast cancer.
Clipping of Lymph Nodes May Aid Axillary Surgery in Breast Cancer
In clinically node-positive breast cancer, clipping of lymph nodes may induce higher rates of sentinel lymph node surgery after neoadjuvant chemotherapy.